Collegium Pharmaceutical
COLL
21.93
+0.05
+0.23%
Collegium Pharmaceutical
US · COLL
#3535 by market cap
Listed 2015
21.93
+0.05
+0.23%
Live - 5344 symbols - heartbeat 209s ago
· 2026-10-08 08:33
Pre-market
22.01
+0.36%
After-hours
21.93
0.00%
- Market cap
- 679.81M
- P/E (TTM)i
- 17.27
- P/Bi
- 2.18
- EPSi
- 1.73
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on COLL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 1.3 percentage points.
Institutional ownership
- Held by institutions
- 126.77% +1.26pp
- Institutions
- 340 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund98.14%
Hedge Fund20.73%
Public Company4.77%
Government Pension Fund1.23%
Individual/Insider1.12%
Private Company0.75%
Family Office/Trust0.38%
Insurance Company0.36%
Bank/Investment Bank0.26%
Top holders as of 2026-06-30
BlackRock
16.71% · 5.44M sh
Janus Henderson Group plc
6.60% · 2.15M sh
Millennium Management LLC
5.59% · 1.82M sh
Fuller & Thaler Asset Management, Inc.
5.02% · 1.63M sh
Principal Global Investors, LLC
5.01% · 1.63M sh
Vanguard Capital Management, LLC
4.95% · 1.61M sh
State Street Global Advisors
4.70% · 1.53M sh
MFS Investment Management
4.32% · 1.41M sh
Renaissance Technologies Corp.
4.20% · 1.37M sh
Eventide Asset Management, LLC
4.18% · 1.36M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 30 sells
| Name | Role | Stake |
|---|---|---|
| Colleen Tupper | Chief Financial Officer | 0.19% |
| John Fallon | Independent Director | 0.17% |
| Gino Santini | Lead Independent Director | 0.13% |
| Michael Heffernan | Chairperson | 0.13% |
| John Freund | Independent Director | 0.13% |
| Vikram Karnani | Chief Executive Officer | 0.12% |
| Thomas Smith | Chief Medical Officer | 0.11% |
| Rita Balice-Gordon | Independent Director | 0.06% |
| Gwen A. Melincoff | Independent Director | 0.04% |
| Nancy Lurker | Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Scott Dreyer | Executive Vice President | Intent to Sell (Form 144) | -27,419 | $22.00 |
| 2026-07-16 | John Fallon | Independent Director | Intent to Sell (Form 144) | -13,920 | $35.73 |
| 2026-07-14 | John Fallon | Independent Director | Intent to Sell (Form 144) | -8,095 | $36.32 |
| 2026-06-07 | Gino Santini | Lead Independent Director | Derivative Exercise and Retained | +8,700 | $16.49 |
| 2026-05-17 | John Freund | Independent Director | Open Market Disposition | -20 | $34.05 |
| 2026-05-14 | John Freund | Independent Director | Derivative Exercise and Sale | -4,127 | $16.49–34.54 |
| 2026-05-14 | John Freund | Independent Director | Derivative Exercise and Retained | +4,573 | $16.49 |
| 2026-05-13 | John Freund | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Nancy Lurker | Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Garen Bohlin | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Gino Santini | Lead Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Carlos Paya | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Rita Balice-Gordon | Independent Director | Other Acquisition | +8,741 | -- |
| 2026-05-13 | Michael Donovan | Independent Director | Other Acquisition | +17,482 | -- |
| 2026-05-12 | Nancy Lurker | Director | Open Market Disposition | -4,500 | $35.97 |
| 2026-05-10 | Garen Bohlin | Independent Director | Derivative Exercise and Sale | -8,700 | $16.49–37.18 |
| 2026-03-17 | David Dieter | Executive Vice President | Automatic Disposition | -13,976 | $34.92 |
| 2026-03-16 | David Dieter | Executive Vice President | Sale to Issuer | -8,840 | $35.72 |
| 2026-03-08 | David Dieter | Executive Vice President | Automatic Disposition | -6,224 | $36.65 |
| 2026-03-02 | Scott Dreyer | Executive Vice President | Automatic Disposition | -49,976 | $40.36–40.99 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:33:16 · For reference only, not investment advice and not tailored to your situation.